Table 3.
The strength of recommendations concerning interventions in the treatment of osteoporosis Note: The grade of recommendation shown in this table relates to the strength of the evidence on which the recommendation is based as defined by SIGN (see Appendix 1). It does not reflect the clinical importance of the recommendation.
| Intervention | BMD Improvement | Decrease Vertebral Fracture Rate | Decrease Hip Fracture Rate |
|---|---|---|---|
| Alendronate [[39], [40], [41]] | A | A | A |
| Calcitriol/Alfacalcidol [42,43] | A | A | A |
| Calcium [16,17] | A | A | – |
| Calcium + vitamin D [16,44] | A | – | A |
| Denosumab [45] | A | A | A |
| Ibandronate [46,47] | A | A | – |
| Menopausal Hormone Therapy [48] | A | A | A |
| Raloxifene [49] | A | A | – |
| Risedronate [50,51] | A | A | A |
| Romosozumab [52] | A | A | – |
| r-PTH/teriparatide [53,54] | A | A | – |
| Tibolone [55] | A | a | – |
| Zoledronate [56] | A | A | A |
BMD, bone mineral density.
a
Effect seen in post-hoc analysis in selected groups of patients.